Why the study?
Are F11R genetic variants and elevated circulatory soluble JAM-A (sJAM-A) levels associated with an increased risk of recurrent myocardial infarction in patients with symptomatic coronary artery disease?
Cohort (n=833)
Investigators assessing clinical outcomes were blinded to clinical manifestations and laboratory results
No
Are F11R genetic variants and elevated circulatory soluble JAM-A (sJAM-A) levels associated with an increased risk of recurrent myocardial infarction in patients with symptomatic coronary artery disease?
Answers are grounded in this paper and cite their sources.
Identifies F11R genetic variants and elevated circulatory sJAM-A as independent predictors of recurrent myocardial infarction in CAD patients and reveals a prothrombotic homophilic interaction between sJAM-A and platelet transmembrane-JAM-A.
Genetic predisposition through F11R-single-nucleotide variation (SNV) influences circulatory soluble junctional adhesion molecule-A (sJAM-A) levels in coronary artery disease (CAD) patients. Homozygous carriers of the minor alleles (F11R-SNVs rs2774276, rs790056) show enhanced levels of thrombo-inflammatory sJAM-A. Both F11R-SNVs and sJAM-A are associated with worse prognosis for recurrent myocardial infarction in CAD patients. Platelet surface-associated JAM-A correlate with platelet activation markers in CAD patients. Activated platelets shed transmembrane-JAM-A, generating proinflammatory sJAM-A and JAM-A-bearing microparticles. Platelet transmembrane-JAM-A and sJAM-A as homophilic interaction partners exaggerate thrombotic and thrombo-inflammatory platelet monocyte interactions. Therapeutic strategies interfering with this homophilic interface may regulate thrombotic and thrombo-inflammatory platelet response in cardiovascular pathologies where circulatory sJAM-A levels are elevated.
No takes yet. Share an insight, caveat, or question.
Rath et al. (2022) conducted a cohort in Symptomatic coronary artery disease (chronic coronary syndrome or acute coronary syndrome) (n=833). Elevated serum sJAM-A (>1.71 ng/mL) and F11R-SNV minor allele homozygosity (rs2774276, rs790056) vs. Lower serum sJAM-A (≤1.71 ng/mL) and F11R-SNV major allele carriers was evaluated on Recurrent myocardial infarction (HR 2.95, 95% CI 1.59-5.46, p=<0.001 (Holm-adjusted 0.003)).
Synapse has enriched 10 related papers. Consider them for comparative context: